Business Context and Reporting Period
This Form 8-K filing by BioSig Technologies, Inc. (BSGM) reports a material definitive agreement entered into on November 8, 2023, with a closing date of November 13, 2023. The filing details a registered direct offering of common stock and warrants to an institutional investor. Note: The request metadata references "Streamex Corp.," but the filing text explicitly identifies the registrant as BioSig Technologies, Inc.
Key Financial Metrics
- Gross Proceeds: Approximately $2.5 million (calculated from 6,996,922 shares at $0.3573 per share).
- Net Proceeds: Approximately $2.2 million after deducting fees and expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, plus $50,000 for non-accountable expenses and $15,950 for clearing fees.
- Placement Agent Warrants: 489,785 warrants issued to the agent (7.0% of shares sold) with an exercise price of $0.4466.
Material Changes and Transaction Details
The Company issued 6,996,922 shares of Common Stock at a purchase price of $0.3573 per share. The offering included two classes of warrants:
- Series A Warrants: To purchase up to 6,996,922 shares; expire five years from issuance.
- Series B Warrants: To purchase up to 6,996,922 shares; expire eighteen months from issuance.
- Exercise Price: $0.3573 per share for both Series A and Series B warrants.
- Exercisability: Warrants become exercisable upon stockholder approval or, if permitted by Nasdaq rules, upon payment of an additional $0.125 per share.
The filing does not provide comparative financial metrics (revenue, profit, cash flow, or debt) for the prior period as this is a current report on a specific transaction rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management intends to use the net proceeds for working capital and general corporate purposes. The filing includes a standard disclaimer that the Securities Purchase Agreement and warrant terms are not intended as a document for investors to obtain factual information about the current state of affairs, directing investors to other SEC filings for such data. No specific forward-looking guidance regarding revenue or earnings was provided in this text.
Investor Verification Checklist
- Verify the exact net proceeds received ($2.2 million) against the gross proceeds and fee structure.
- Confirm the dilution impact of the 6,996,922 new shares and the potential dilution from 13,993,844 total warrants (Series A, Series B, and Placement Agent).
- Review the Nasdaq rules regarding the alternative exercise condition (payment of $0.125 per share) to understand immediate exercisability.
- Check subsequent filings for the status of stockholder approval required for warrant exercise.
- Confirm the company name discrepancy between the request metadata (Streamex Corp.) and the filing (BioSig Technologies, Inc.).